Free Neurology CME

  • FREE

    ScientiaCME Neuropsychiatry-Neurology

    Target Audience: Neurologists

    See full details chevron_right
    • Cost: Free
    • Credit hours: 3.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    ScientiaCME Transthyretin-mediated amyloidosis (ATTR): successful identification and its role in optimizing outcomes

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Transthyretin-mediated amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils. The role of the TTR protein is to transport thyroxine and retinol-binding proteins, and it is vital for cognition, nerve regeneration, and axonal growth. TTR itself is innately amyloidogenic even without the presence of genetic mutations, which may account for wild-type ATTR (wtATTR), while a hereditary form of ATTR (hATTR) may be passed to offspring through autosomal dominant inheritance. Left untreated, the average life expectancy of ATTR is 3 to 15 years from symptom onset.

    Target Audience:
    The following HCPs: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 15, 2023
    • Expiration of CME credit: December 15, 2025
  • FREE

    ScientiaCME Straightening out our approach to the management of cervical dystonia: optimizing treatment strategies

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Cervical dystonia is the most common focal dystonia, characterized by involuntary muscular contractions resulting in abnormal head, neck, and shoulder movements in addition to posture that can cause tremor and pain. Early-onset dystonia can begin in infancy, childhood, or adolescence, and it generally progresses from focal to generalized. Adult-onset dystonia usually affects the upper part of the body; the origin of the dystonia determines the risk of spread. Cervical dystonia may appear as torticollis, laterocollis, anterocollis, or retrocollis. It may be distinguished from nondystonic hand tremor and essential tremor by the absence of limb tremor and the manner of neck movement. However, it is more difficult to distinguish from pseudodystonias, resulting in misdiagnosis and inappropriate treatment.

    Target Audience:

    The following HCPs: medical neurologists; physician assistants, nurse practitioners, and pharmacists who practice in neurology; and other clinicians who commonly encounter patients with cervical dystonia. 

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: May 19, 2023
    • Expiration of CME credit: May 19, 2025
  • FREE

    Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care

    Alzheimer Disease (AD) is a degenerative disease that most commonly affects the elderly, although it is occasionally detected as early as middle age. AD accounts for over half of all diagnosed dementia, the prevalence of which is increasing. Once there is a diagnosis of probable AD, one must determine which pharmacotherapy, if any, is most appropriate for treatment of the patient. The literature suggests that gaps in care on the part of healthcare professionals exist. While some physicians continue to use the antiquated, nonspecific term “senile dementia” as a descriptive diagnosis of AD, perhaps suggesting a lack of understanding of the gravity of the disease state or its associated pathophysiology, other report feeling uncertain at times about now to best diagnosis of the disease, particularly in its very early stages. Moreover, a number of different practice guidelines have been updated recently, and HCPs are often unable to keep up with the publishing of literature and evolution of clinical practice.

    Target Audience:

    Healthcare professionals specializing in: neurology, gerontology, internal medicine, palliative care, or those who otherwise commonly care for patients with AD or who frequently encounter them or their caregivers in practice.

    By the end of the session the participant will be able to:

    • Describe what is presently known about the pathophysiology of AD.
    • Describe the challenges associated with diagnosis and treatment of ADDiscuss the neuropathophysiology of AD and how it relates to presently available AD treatments mechanisms.
    • Identify the present treatment options currently available for management of AD and apply them to patient cases using evidence-based medicine.
    • Describe emerging drug therapies in the treatment of AD.
    • Evaluate a treatment plan for a specific patient based on degree of AD to optimize safety and efficacy, suggesting modifications for improvement.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/09/2020
    • Expiration of CME credit: 07/09/2022
  • FREE

    Updates in the medical management of Pompe disease

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Pompe disease (PD) is a progressive, often fatal, autosomal recessive, neuromuscular disorder caused by mutations of the α-glucosidase gene on chromosome 17. PD is characterized by glycogen accumulation in skeletal, cardiac and smooth muscles due to a deficiency in α-glucosidase (GAA), an important lysosomal enzyme responsible for glycogen catabolism. PD is categorized into three groups based on symptoms and age of onset. The classic infantile form presents in the first year of life, usually in the first two months, with hypertrophic cardiomyopathy. The non-classic infantile form presents later in the first year of life, without or with less severe cardiomyopathy. The late onset form of PD presents any time after one year of life, usually without cardiac complications.

    PD is rare, with one study estimating the incidence in the U.S. to be 1 in 22,000 births. The biggest risk factor for the disease is genetics; at conception, each sibling of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being not a carrier. Nonspecific diagnostic findings for PD may include abnormal EMG, elevated serum creatine kinase, elevated transaminases and elevated lactate dehydrogenase. A definitive diagnosis for PD involves a dried blood spot test to determine GAA enzyme activity level; reduced GAA activity (less than 40% of normal) is indicative of a positive diagnosis. A gene mutation analysis, or another GAA enzyme test using a different area of tissue, is recommended to confirm the diagnosis. The disease is not uncommonly undiagnosed or is misdiagnosed, representing one practice gap that continued HCP education may address, particularly given that earlier treatment may minimize rapid and irreversible disease progression.

    Target Audience:

    The following HCPs: Neurologists, pediatricians, and primary care physicians; physician assistants and nurse practitioners in those areas of specialty; pharmacists who practice in specialty pharmacies that treat patients with rare diseases; and any other HCPs with an interest in or who may clinically encounter patients with PD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 29, 2022
    • Expiration of CME credit: April 29, 2024
  • FREE

    Contemporary challenges and updates and in the diagnosis and management of Alzheimer’s disease – from early disease onward

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Alzheimer disease (AD) is a degenerative disease that most commonly affects the elderly, although it is occasionally detected as early as middle age. AD’s prevalence has more than doubled since the year 2000, with recent data suggesting that it will double again by the year 2050. In 2020, AD was the seventh-leading cause of death in the US, and the COVID-19 pandemic has further increased AD-related mortality by 16%. Furthermore, AD impacts the family members and loved ones of people with AD. More than 11 million Americans are estimated to provide 15.3 billion hours of unpaid care, with costs expected to exceed $1 trillion by the year 2050.

    AD has traditionally been difficult to diagnose because its onset is oftentimes insidious, with a definitive diagnosis made only on neural tissue examination. The disease is often undetected in its early stages because the symptoms can be similar to cognitive decline that is generally assumed to occur naturally with the aging process, such as forgetfulness and difficulty learning new information. When a patient presents with possible AD, the gathering of information from the family members and specific cognitive tests are used to rule out other possible diseases and to rule in the probable diagnosis of AD. While a number of different practice guidelines are available, but none are recent enough to cover the incorporation of monoclonal antibodies into care and developments in the treatment of early Alzheimer’s disease, including eligible candidates for therapy. Helping the clinician discern the role of these agents merits CME as research suggests that HCPs are unable to keep up with the  publishing of literature and evolution of clinical practice.

    Target Audience:

    The following HCPs: Neurologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in neurology; and any other HCPs with an interest in or who clinically encounter patients with AD or who frequently encounter them or their caregivers in practice.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 7/8/2022
    • Expiration of CME credit: 7/8/2024
  • FREE

    Waking to our potential in the management of narcolepsy and excessive daytime sleepiness: Treatment updates and gaps in care

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Narcolepsy is a neurologic disorder characterized by inappropriate regulation of the sleep-wake cycle and excessive sleepiness during waking hoursAffected individuals may fall asleep at inappropriate times, such as when talking to others, eating, or even driving. Roughly 135,000 to 200,000 people in the United States are estimated to have narcolepsy. Women and men are affected by narcolepsy equally, and most patients begin having symptoms between the ages of 7 and 25 years. The treatment of narcolepsy may be complicated and must be tailored individually after careful evaluation of the patient’s symptoms.

    Target Audience:

    The following HCPs: neurologists, internists, PCPs, psychiatrists; nurse practitioners, physician assistants, and pharmacists who specialize in the aforementioned areas of specialty; and those who otherwise commonly care for or clinically encounter patients with sleep disorders.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 03/22/2023
    • Expiration of CME credit: 03/22/2025